Stryker Corporation $SYK Shares Purchased by Kelleher Financial Advisors

Kelleher Financial Advisors raised its stake in Stryker Corporation (NYSE:SYK) by 208.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,960 shares of the medical technology company’s stock after buying an additional 2,678 shares during the period. Kelleher Financial Advisors’ holdings in Stryker were worth $1,247,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker during the 4th quarter worth approximately $27,000. Finally, DJE Kapital AG acquired a new stake in Stryker during the 4th quarter valued at $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $338.80 on Monday. The company has a fifty day moving average price of $324.61 and a 200 day moving average price of $333.40. The stock has a market cap of $129.95 billion, a P/E ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Piper Sandler decreased their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Truist Financial raised their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday. BTIG Research decreased their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. Finally, Royal Bank Of Canada lowered their price objective on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.